Asia
Research Roundup for Friday, May 24.
Hong Kong is known around the world for its financial might, iconic skyline and international outlook. But it might not be long before the city is known for something totally outside its traditional realm: cutting-edge healthcare solutions.
Eisai Co., Ltd. announced today that Eisai has received approval from “Science Based Targets Initiative” for Eisai’s mid and long-term targets for greenhouse gas reduction.
The decision, which is likely to be appealed, will allow Dana-Farber to license the technology.
The new exploratory data indicated that a larger proportion of patients receiving Entyvio had a clinical response at week 14 compared to those receiving Humira.
The FDA extended the indication for Gattex to pediatric patients one year of age and older with short bowel syndrome.
More than 12,000 buyers visit 2019 fair, up 8% on last year
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate, eribulin mesylate, and MORAb-202 will be given at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2019.
Teijin Limited announced today its establishment of NOMON, Co., Ltd. to sell nutraceutical food and beverages that are scientifically proven to help people maintain their health.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
PRESS RELEASES